Literature DB >> 29482040

Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia.

Lijuan Man1, Xiaoli Lv2, Xiang-Dong Du2, Guangzhong Yin2, Xiaomin Zhu2, Yingyang Zhang2, Jair C Soares3, Xu-Na Yang4, Xingshi Chen5, Xiang Yang Zhang6.   

Abstract

Evidence shows that BDNF may regulate activity-dependent forms of synaptic plasticity underlying learning and memory. Previous studies reported low BDNF levels and cognitive impairment in the early stage of schizophrenia. Our current study aimed to explore the association between serum BDNF and cognitive functions in first-episode drug-naïve (FEDN) patients with schizophrenia, which has been under-investigated. We recruited 80 FEDN patients and 80 healthy controls and examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and serum BDNF in both groups. Patient psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). BDNF levels were significantly lower in patients compared to controls (p < 0.001). The RBANS total score and nearly all indexes (all p < 0.001) except for visuospatial/constructional index (p > 0.05) were significantly lower in patients than controls. No significant correlation was found between BDNF and any index or total scores of RBANS in either patients or healthy controls (all p > 0.05). However, the PANSS negative subscale score were negatively associated with both the immediate memory and language indexes (both p < 0.005). Our findings suggest that excessive cognitive impairments are present in the early stage of schizophrenia. Low BDNF may contribute to the pathogenesis of schizophrenia, but maybe not to its cognitive impairments.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain-derived neurotrophic factor; Cognition; First-episode psychosis; Schizophrenia; Serum

Mesh:

Substances:

Year:  2018        PMID: 29482040     DOI: 10.1016/j.psychres.2018.02.034

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  22 in total

1.  A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia.

Authors:  Egor Chumakov; Mariia Dorofeikova; Kristina Tsyrenova; Nataliia Petrova
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

2.  CCRT and aerobic exercise: a randomised controlled study of processing speed, cognitive flexibility, and serum BDNF expression in schizophrenia.

Authors:  Yuanyuan Dai; Hongyan Ding; Xiaozi Lu; Xiumei Wu; Chunhua Xu; Tingting Jiang; Liang Ming; Zhong Xia; Chuanfu Song; Hongxian Shen; Wei Hao; Shucai Huang
Journal:  Schizophrenia (Heidelb)       Date:  2022-10-20

3.  Association of retinal nerve fiber abnormalities with serum CNTF and cognitive functions in schizophrenia patients.

Authors:  Yanhong Liu; Lvzhen Huang; Yongsheng Tong; Jingxu Chen; Dongfang Gao; Fude Yang
Journal:  PeerJ       Date:  2020-06-02       Impact factor: 2.984

4.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 5.  Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies.

Authors:  Wei Zheng; Wen-Long Jiang; Xun Zhang; Dong-Bin Cai; Jia-Wei Sun; Fei Yin; Peng-Cheng Ren; Min Zhao; Hua-Wang Wu; Ying-Qiang Xiang; Wan-Nian Liang; Wei Zheng
Journal:  Psychiatr Q       Date:  2021-03-22

Review 6.  Brain-derived neurotrophic factor and schizophrenia.

Authors:  Pasquale Di Carlo; Giovanna Punzi; Gianluca Ursini
Journal:  Psychiatr Genet       Date:  2019-10       Impact factor: 2.574

7.  Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls.

Authors:  Yu-Jie Chiou; Tiao-Lai Huang
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 8.  Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology.

Authors:  Lawrence H Yang; Bernalyn Ruiz; Amar D Mandavia; Margaux M Grivel; Liang Y Wong; Michael R Phillips; Matcheri S Keshavan; Huijun Li; Jeffrey A Lieberman; Ezra Susser; Larry J Seidman; William S Stone
Journal:  Schizophr Res       Date:  2020-04-05       Impact factor: 4.939

Review 9.  BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.

Authors:  Rodrigo R Nieto; Andrea Carrasco; Sebastian Corral; Rolando Castillo; Pablo A Gaspar; M Leonor Bustamante; Hernan Silva
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 4.157

10.  The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients.

Authors:  Kiyokazu Atake; Tomoyuki Nakamura; Nobuhisa Ueda; Hikaru Hori; Asuka Katsuki; Reiji Yoshimura
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.